Medicus Pharma Ltd. (NASDAQ: MDCX), a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate, while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect® and Teverelix® Programs.
CD228Vnow represents the principal strategic priority for Medicus, with initial development concentrated on establishing clinical proof-of-concept in a carefully selected tumor population, supported by an integrated clinical and translational strategy. Based on the existing biological, translational and clinical foundation, melanoma represents a compelling initial development opportunity, particularly in patients with relapsed or refractory disease.
The addition of CD228V represents a paradigm shift in Medicus’ clinical development portfolio and establishes precision oncology as a central component of the Company’s strategy.
CD228V is a second-generation ADC targeting melanotransferrin/CD228 in solid tumors. The program is supported by an active U.S. Investigational New Drug (IND), a first-in-human Phase 1 clinical study (NCT06799533), and substantial prior scientific, translational, and clinical development.
The Company believes successful demonstration of clinical proof-of-concept in melanoma, supported by an integrated translational and biomarker strategy, could provide an important foundation for subsequent development in other CD228-expressing solid tumors.
Shares in MDCX gained half a cent, or 3%, to 18 cents.
Related Stories
